Results 11 to 20 of about 46,511 (209)

Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from Candida albicans—In Silico, In Vitro and In Vivo Approaches

Journal of Fungi, 2021
The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen Candida albicans ...
André L. S. Santos, Lys A. Braga-Silva, Diego S. Gonçalves, Lívia S. Ramos, Simone S. C. Oliveira, Lucieri O. P. Souza, Vanessa S. Oliveira, Roberto D. Lins, Marcia R. Pinto, Julian E. Muñoz, Carlos P. Taborda, Marta H. Branquinha   +11 more
doaj   +1 more source

Docking and Molecular Dynamic Simulations Study to Search Curcumin Analogue Compounds as Potential Inhibitor Against SARS-CoV-2: A Computational Approach

Jurnal Kimia Sains dan Aplikasi, 2021
Coronavirus is a pandemic in the world. It requires researchers and scientists to work hard to find a vaccine or drug to inhibit the development of the coronavirus. Many drugs have been used, such as remdesivir, lopinavir, and chloroquine.
Neni Frimayanti, Adel Zamri, Yum Eryanti, Noval Herfindo, Veza Azteria   +4 more
doaj   +1 more source

Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study

Frontiers in Medicine, 2021
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients.Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID ...
Augusto Di Castelnuovo, Simona Costanzo, Andrea Antinori, Nausicaa Berselli, Lorenzo Blandi, Marialaura Bonaccio, Raffaele Bruno, Raffaele Bruno, Roberto Cauda, Roberto Cauda, Alessandro Gialluisi, Giovanni Guaraldi, Lorenzo Menicanti, Marco Mennuni, Ilaria My, Agostino Parruti, Giuseppe Patti, Stefano Perlini, Stefano Perlini, Francesca Santilli, Carlo Signorelli, Giulio G. Stefanini, Alessandra Vergori, Walter Ageno, Luca Aiello, Piergiuseppe Agostoni, Piergiuseppe Agostoni, Samir Al Moghazi, Rosa Arboretti, Filippo Aucella, Greta Barbieri, Martina Barchitta, Alessandro Bartoloni, Carolina Bologna, Paolo Bonfanti, Paolo Bonfanti, Lucia Caiano, Laura Carrozzi, Antonio Cascio, Giacomo Castiglione, Mauro Chiarito, Arturo Ciccullo, Antonella Cingolani, Antonella Cingolani, Francesco Cipollone, Claudia Colomba, Crizia Colombo, Francesco Crosta, Giovanni Dalena, Chiara Dal Pra, Gian Battista Danzi, Damiano D'Ardes, Katleen de Gaetano Donati, Francesco Di Gennaro, Giuseppe Di Tano, Gianpiero D'Offizi, Tommaso Filippini, Francesco Maria Fusco, Carlo Gaudiosi, Ivan Gentile, Giancarlo Gini, Elvira Grandone, Gabriella Guarnieri, Gennaro L. F. Lamanna, Giovanni Larizza, Armando Leone, Veronica Lio, Angela Raffaella Losito, Gloria Maccagni, Stefano Maitan, Sandro Mancarella, Rosa Manuele, Massimo Mapelli, Massimo Mapelli, Riccardo Maragna, Riccardo Maragna, Lorenzo Marra, Giulio Maresca, Claudia Marotta, Franco Mastroianni, Maria Mazzitelli, Alessandro Mengozzi, Francesco Menichetti, Jovana Milic, Filippo Minutolo, Beatrice Molena, R. Mussinelli, Cristina Mussini, Maria Musso, Anna Odone, Marco Olivieri, Emanuela Pasi, Annalisa Perroni, Francesco Petri, Biagio Pinchera, Carlo A. Pivato, Venerino Poletti, Claudia Ravaglia, Marco Rossato, Marianna Rossi, Anna Sabena, Francesco Salinaro, Vincenzo Sangiovanni, Carlo Sanrocco, Laura Scorzolini, Raffaella Sgariglia, Paola Giustina Simeone, Michele Spinicci, Enrico Maria Trecarichi, Giovanni Veronesi, Roberto Vettor, Andrea Vianello, Marco Vinceti, Marco Vinceti, Elena Visconti, Laura Vocciante, Raffaele De Caterina, Licia Iacoviello, Licia Iacoviello, The COVID-19 RISK and Treatments (CORIST) Collaboration   +119 more
doaj   +1 more source

Sex differences in hypertension among people living with HIV after initiation of antiretroviral therapy

Frontiers in Cardiovascular Medicine, 2022
BackgroundHypertension is common in people living with HIV (PLWH) on antiretroviral therapy (ART). In the general population and in experimental animal models, the incidence of hypertension is greater in males than in females, especially during the ...
Sepiso K. Masenga, Sepiso K. Masenga, Joreen P. Povia, Katongo H. Mutengo, Benson M. Hamooya, Selestine Nzala, Douglas C. Heimburger, Douglas C. Heimburger, Sody M. Munsaka, Fernando Elijovich, Kaushik P. Patel, Annet Kirabo   +11 more
doaj   +1 more source

CAQ Corner: Basic concepts of transplant immunology

, 2022
Liver Transplantation, EarlyView.
Amanda Cheung, Josh Levitsky
wiley   +1 more source

Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study [PDF]

, 2014
Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or
. . . ]., Anna Degli Antoni, Anna Maria Marconi, Arsenio Spinillo, CAPRETTI, MARIA GRAZIA, Carmela Pinnetti, Daniela Francisci, Enrica Tamburrini, FALDELLA, GIACOMO, Giulia Masuelli, Giuseppina Liuzzi, Marco Floridia, Marina Ravizza, MARSICO, CONCETTA, Marta Fiscon, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [. . ., Pasquale Martinelli, Vania Giacomet   +17 more
core   +1 more source

Development of In Situ Self-Assembly Nanoparticles to Encapsulate Lopinavir and Ritonavir for Long-Acting Subcutaneous Injection

Pharmaceutics, 2021
Most antiretroviral medications for human immunodeficiency virus treatment and prevention require high levels of patient adherence, such that medications need to be administered daily without missing doses.
Irin Tanaudommongkon, Asama Tanaudommongkon, Xiaowei Dong   +2 more
doaj   +1 more source

Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. [PDF]

, 2011
In resource-limited settings, many patients, with no prior protease inhibitor (PI) treatment on a second-line, high genetic barrier, ritonavir-boosted PI-containing regimen have virologic ...
Arribas, Bangsberg, Barreiro, Berg, Carolina Malavazzi, Cassani, Delaugerre, El-Khatib, Eric Decloedt, Frost, Gandhi, Gardner, Gary Maartens, Gathe, Gert Uves van Zyl, Helen McIlleron, Huang, Jean B Nachega, Kosuge, Lize van der Merwe, Michele Zeier, Mo, Monica Gandhi, Peter Smith, Pujades-Rodriguez, Quiros-Roldan, Riddler, Thijs E van Mens, van Zyl, van Zyl, Yong Huang   +30 more
core   +3 more sources

Clinical impact of double protease inhibitor boosting with Lopinavir/Ritonavir and Amprenavir as part of salvage antiretroviral therapy [PDF]

, 2003
Purpose: Double protease inhibitor (PI) boosting is being explored as a new strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug interaction leads to decreased drug levels of either or both PIs, double PI boosting could lead to ...
Abdurrahman, Z., Gough, K., Kovacs, C., Loutfy, M., Phillips, E., Raboud, J., Rachlis, A., Rubin, G., Thompson, C., Tseng, A., Walmsley, S.   +10 more
core   +2 more sources

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)

South African Journal of Science, 2015
Currently, the treatment of choice of HIV/AIDS in South Africa is the multidrug combination regimen known as HAART (highly active antiretroviral treatment).
Gbenga A. Adefolaju, Katherine E. Theron, Margot J. Hosie   +2 more
doaj   +1 more source